[A Patient Who Had Postoperative Three-Field Lymph Node Recurrence of Cancer of the Esophagogastric Junction Obtains Complete Response by DCF Treatment]

Gan To Kagaku Ryoho. 2023 Dec;50(12):1323-1326.
[Article in Japanese]

Abstract

A 64-year-old woman underwent left-thoracoabdominal esophagectomy and esophagojejunostomy for cancer of the esophagogastric junction. The pathological examination of the resected specimen showed a poorly squamous cell carcinoma (SCC). The pathological stage was pT3, pN1, sM0, and fStage Ⅲ. Three months after surgery, an SCC antigen related to a tumor marker was found to be outside the normal range, and CT showed lymph node recurrence of the three fields(No. 101R, No. 104RL, No. 106recRL, No. 106pre, and No. 16b1). Because the lymph node recurrence was in the three fields, we performed systemic chemotherapy with docetaxel, cisplatin(CDDP), and 5-fluorouracil(5-FU)(collectively, DCF). After the patient received 2 courses of DCF therapy, the lymph nodes where the recurrent occurred decreased in size(partial response), and SCC became within normal range. She received additional chemotherapy with 2 courses of DCF and achieved a complete response. Currently, she has been alive without recurrence for 7 years and 9 months after 4 courses of DCF therapy. We think that we can select DCF therapy as a first-line treatment for lymph node recurrence alone but not for CRT with FP.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Anastomosis, Surgical
  • Biomarkers, Tumor
  • Carcinoma, Squamous Cell*
  • Cisplatin
  • Esophagogastric Junction / surgery
  • Female
  • Fluorouracil
  • Humans
  • Lymph Nodes
  • Middle Aged
  • Pathologic Complete Response

Substances

  • Biomarkers, Tumor
  • Cisplatin
  • Fluorouracil